BME · Insider Trading
Blackrock Health Sciences Trust
Every open-market purchase and sale reported by BME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | H Erin Xie | — | MIXED | — | −$479.39K |
| 2026-02-03 | Xiang Liu | — | MIXED | — | −$16.29K |
| 2025-02-04 | Kyle McClements | — | MIXED | — | −$26.25K |
| 2025-02-04 | Christopher Accettella | — | MIXED | — | −$8.27K |
| 2025-02-04 | Xiang Liu | — | MIXED | — | −$11.50K |
| 2025-02-04 | H Erin Xie | — | MIXED | — | −$551.24K |
| 2024-04-30 | Kyle McClements | — | — | — | — |
| 2024-02-02 | Kyle McClements | — | MIXED | — | −$25.95K |
| 2024-02-02 | Xiang Liu | — | MIXED | — | −$7.82K |
| 2024-02-02 | Christopher Accettella | — | MIXED | — | −$8.41K |
| 2024-02-02 | H Erin Xie | — | MIXED | — | −$620.00K |
| 2023-02-02 | Xiang Liu | — | MIXED | — | −$4.19K |
| 2023-02-02 | Kyle McClements | — | MIXED | — | −$26.84K |
| 2023-02-02 | Christopher Accettella | — | MIXED | — | −$8.99K |
| 2023-02-02 | Jeffrey Gene Lee | — | MIXED | — | −$8.91K |
| 2023-02-02 | H Erin Xie | — | MIXED | — | −$608.39K |
| 2022-02-03 | Christopher Accettella | — | MIXED | — | −$9.16K |
| 2022-02-03 | Kyle McClements | — | MIXED | — | −$28.50K |
| 2022-02-02 | Jeffrey Gene Lee | — | MIXED | — | −$3.22K |
| 2022-02-02 | Xiang Liu | — | A | +271 deriv. | — |
| 2022-02-02 | H Erin Xie | — | MIXED | — | −$704.31K |
| 2021-02-02 | Jeffrey Gene Lee | — | A | +203 deriv. | — |
| 2021-02-02 | Christopher Accettella | — | MIXED | — | −$10.91K |
| 2021-02-02 | Kyle McClements | — | MIXED | — | −$37.14K |
| 2021-02-02 | H Erin Xie | — | MIXED | — | −$663.95K |
| 2020-02-04 | Christopher Accettella | — | MIXED | — | −$6.51K |
| 2020-02-04 | H Erin Xie | — | MIXED | — | −$468.40K |
| 2020-02-04 | Kyle McClements | — | MIXED | — | −$24.83K |
| 2019-07-02 | Cynthia Egan | Director | Buy | +3,737 | +$145.44K |
| 2019-02-04 | Christopher Accettella | — | MIXED | — | −$3.29K |
| 2019-02-04 | Kyle McClements | — | MIXED | — | −$12.90K |
| 2019-02-04 | H Erin Xie | — | MIXED | — | −$173.11K |
| 2018-10-17 | Catherine A. Lynch | Director | A | +49 deriv. | — |
| 2018-10-17 | W Carl Kester | Director | A | +32 deriv. | — |
| 2018-10-17 | Robert Glenn Hubbard | Director | A | +125 deriv. | — |
| 2018-10-17 | Richard Cavanagh | Director | A | +109 deriv. | — |
| 2018-10-17 | Michael J Castellano | Director | A | +74 deriv. | — |
| 2018-10-17 | Karen P Robards | Director | A | +16 deriv. | — |
| 2018-07-17 | Michael J Castellano | Director | A | +74 deriv. | — |
| 2018-07-17 | W Carl Kester | Director | A | +32 deriv. | — |
| 2018-07-17 | Richard Cavanagh | Director | A | +109 deriv. | — |
| 2018-07-17 | Karen P Robards | Director | A | +16 deriv. | — |
| 2018-07-17 | Catherine A. Lynch | Director | A | +49 deriv. | — |
| 2018-07-17 | Robert Glenn Hubbard | Director | A | +125 deriv. | — |
| 2018-04-17 | Michael J Castellano | Director | A | +89 deriv. | — |
| 2018-04-17 | W Carl Kester | Director | A | +38 deriv. | — |
| 2018-04-17 | Richard Cavanagh | Director | A | +130 deriv. | — |
| 2018-04-17 | Karen P Robards | Director | A | +19 deriv. | — |
| 2018-04-17 | Catherine A. Lynch | Director | A | +59 deriv. | — |
| 2018-04-17 | Robert Glenn Hubbard | Director | A | +149 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| H Erin Xie | — | 11,449 | $522.32K |
| Christopher Accettella | — | 1,022 | $46.65K |
| Kyle McClements | — | 593 | $27.05K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BME quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.